EE04750B1 - HIV-proteaasi inhibiitorite valmistamismeetod - Google Patents

HIV-proteaasi inhibiitorite valmistamismeetod

Info

Publication number
EE04750B1
EE04750B1 EEP200000568A EEP200000568A EE04750B1 EE 04750 B1 EE04750 B1 EE 04750B1 EE P200000568 A EEP200000568 A EE P200000568A EE P200000568 A EEP200000568 A EE P200000568A EE 04750 B1 EE04750 B1 EE 04750B1
Authority
EE
Estonia
Prior art keywords
preparation
protease inhibitors
hiv protease
hiv
inhibitors
Prior art date
Application number
EEP200000568A
Other languages
English (en)
Estonian (et)
Inventor
Al-Farhan Emile
D. Deininger David
Mcghie Stephen
O`Callaghan John
Stuart Robertson Mark
Rodgers Keith
John Rout Stephen
Singh Hardev
Dennis Tung Roger
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of EE200000568A publication Critical patent/EE200000568A/xx
Publication of EE04750B1 publication Critical patent/EE04750B1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
EEP200000568A 1998-03-20 1999-03-18 HIV-proteaasi inhibiitorite valmistamismeetod EE04750B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9805898.5A GB9805898D0 (en) 1998-03-20 1998-03-20 Process for the sythesis of hiv protease inhibitors
PCT/GB1999/000852 WO1999048885A1 (en) 1998-03-20 1999-03-18 Process for the synthesis of hiv protease inhibitors

Publications (2)

Publication Number Publication Date
EE200000568A EE200000568A (et) 2002-02-15
EE04750B1 true EE04750B1 (et) 2006-12-15

Family

ID=10828884

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000568A EE04750B1 (et) 1998-03-20 1999-03-18 HIV-proteaasi inhibiitorite valmistamismeetod

Country Status (32)

Country Link
US (1) US6281367B1 (xx)
EP (1) EP1066276B1 (xx)
JP (1) JP3363439B2 (xx)
KR (1) KR100555278B1 (xx)
CN (1) CN1308319C (xx)
AP (1) AP1226A (xx)
AT (1) ATE242772T1 (xx)
AU (1) AU751534B2 (xx)
BR (1) BR9908970A (xx)
CA (1) CA2324217C (xx)
CZ (1) CZ299193B6 (xx)
DE (1) DE69908761T2 (xx)
DK (1) DK1066276T3 (xx)
EA (1) EA003022B1 (xx)
EE (1) EE04750B1 (xx)
ES (1) ES2203090T3 (xx)
GB (1) GB9805898D0 (xx)
HK (1) HK1032047A1 (xx)
HR (1) HRP20000609B1 (xx)
HU (1) HUP0105439A3 (xx)
ID (1) ID26587A (xx)
IL (1) IL138127A (xx)
IS (1) IS2273B (xx)
NO (1) NO317648B1 (xx)
NZ (1) NZ506563A (xx)
PL (1) PL201810B1 (xx)
PT (1) PT1066276E (xx)
RS (1) RS49954B (xx)
SK (1) SK283939B6 (xx)
TR (1) TR200002698T2 (xx)
WO (1) WO1999048885A1 (xx)
ZA (1) ZA200004482B (xx)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843946A (en) 1992-08-25 1998-12-01 G.D. Searle & Co. α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US6548706B2 (en) * 1999-12-23 2003-04-15 Aerojet Fine Chemicals Llc Preparation of 2S,3S-N-isobutyl-N-(2-hydroxy-3-amino-4-phenylbutyl) -p-nitrobenzenesulfonylamide hydrochloride and other derivatives of 2-hydroxy-1,3-diamines
EP2314564A3 (en) * 1999-12-23 2012-04-04 Ampac Fine Chemicals LLC Improved preparation of 2S,3S-N-isobutyl-N-(2-hydroxy-3-amino-4-phenylbutyl)-p-nitrobenzenesulfonylamide hydrochloride and other derivatives of 2-hydroxy-1,3-diamines
HUE034389T2 (en) 2002-05-16 2018-02-28 Janssen Sciences Ireland Uc Pseudopolymorphic forms of an HIV protease inhibitor
US7772411B2 (en) 2003-12-23 2010-08-10 Tibotec Pharmaceuticals Ltd. Process for the preparation of (3R,3aS,6aR)-hexahydrofuro [2,3-b] furan-3-yl (1S,2R)-3[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate
AR073248A1 (es) 2008-09-01 2010-10-20 Tibotec Pharm Ltd Proceso para la preparacion de (1s, 2r)-3- ((4-aminofenil) sulfonil) ( isobutil) amino)-1- bencil-2- hidroxipropilcarbamato de (3r, 3as,6ar)- hexahidrofuro-(2,3-b) furan-3- ilo (darunavir) y compuestos intermediarios utiles en dicho proceso.
AP3551A (en) 2010-01-27 2016-01-18 Viiv Healthcare Co Antiviral therapy
WO2012032389A2 (en) 2010-09-10 2012-03-15 Lupin Limited Process for preparation of substantially pure fosamprenavir calcium and its intermediates
CN111233794A (zh) * 2020-03-27 2020-06-05 江巨东 一种安普那韦的精制方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1071930A (zh) * 1991-07-10 1993-05-12 伊莱利利公司 用作治疗艾滋病的人免疫缺陷病毒蛋白酶的抑制剂
US5843946A (en) * 1992-08-25 1998-12-01 G.D. Searle & Co. α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða

Also Published As

Publication number Publication date
EP1066276A1 (en) 2001-01-10
IS2273B (is) 2007-07-15
CA2324217A1 (en) 1999-09-30
ZA200004482B (en) 2001-11-28
CN1308319C (zh) 2007-04-04
CZ299193B6 (cs) 2008-05-14
EA003022B1 (ru) 2002-12-26
YU55900A (sh) 2003-02-28
HUP0105439A2 (en) 2002-06-29
IS5605A (is) 2000-08-29
CZ20003457A3 (cs) 2001-04-11
CN1293668A (zh) 2001-05-02
WO1999048885A1 (en) 1999-09-30
EP1066276B1 (en) 2003-06-11
GB9805898D0 (en) 1998-05-13
HRP20000609A2 (en) 2001-04-30
AP1226A (en) 2003-11-21
CA2324217C (en) 2008-02-19
AP2000001911A0 (en) 2000-09-30
KR100555278B1 (ko) 2006-03-03
RS49954B (sr) 2008-09-29
NO20004664L (no) 2000-09-19
SK283939B6 (sk) 2004-05-04
US6281367B1 (en) 2001-08-28
KR20010042022A (ko) 2001-05-25
ATE242772T1 (de) 2003-06-15
TR200002698T2 (tr) 2000-12-21
HK1032047A1 (en) 2001-07-06
NO317648B1 (no) 2004-11-29
HUP0105439A3 (en) 2002-08-28
IL138127A0 (en) 2001-10-31
AU2947599A (en) 1999-10-18
EA200000859A1 (ru) 2001-04-23
ID26587A (id) 2001-01-18
DK1066276T3 (da) 2003-10-06
DE69908761T2 (de) 2004-02-19
AU751534B2 (en) 2002-08-22
JP3363439B2 (ja) 2003-01-08
PL201810B1 (pl) 2009-05-29
EE200000568A (et) 2002-02-15
JP2002507609A (ja) 2002-03-12
DE69908761D1 (de) 2003-07-17
NZ506563A (en) 2003-05-30
PT1066276E (pt) 2003-10-31
PL342602A1 (en) 2001-06-18
IL138127A (en) 2003-10-31
NO20004664D0 (no) 2000-09-19
HRP20000609B1 (en) 2006-05-31
ES2203090T3 (es) 2004-04-01
SK13732000A3 (sk) 2001-08-06
BR9908970A (pt) 2000-11-28

Similar Documents

Publication Publication Date Title
NO20012980D0 (no) Proteaseinhibitorer
CY2007029I1 (el) Μεθοδος για την παρασκευη υποκατεστημενων οκτανοϋλ-αμιδιων
AR028253A1 (es) Inhibidores de la glucogeno fosforilasa
NO995433D0 (no) Protease-inhibitorer
NO995316L (no) Serinproteaseinhibitorer
PT1086076E (pt) Inibidores de sulfonamida de aspartil protease
DK1085981T3 (da) Fremgangsmåde til emballering
NO995434D0 (no) Proteaseinhibitorer
IT1298535B1 (it) Procedimento per la produzione di gamma-butirrolattone
NO995435D0 (no) Protease-inhibitorer
NO995268D0 (no) Proteaseinhibitorer
DE59806475D1 (de) Urokinase-inhibitoren
FI964342A0 (fi) Halogeenimetyyliamideja IL-1beta-proteaasi-inhibiittoreina
EE200000568A (et) HIV-proteaasi inhibiitorite valmistamismeetod
ATE252547T1 (de) Matrixmetalloproteinaseinhibitoren
DK0987356T3 (da) Fremgangsmåde til trækning
DK0864564T3 (da) Særlig fremgangsmåde til fremstillingen af alfa-bromlactamderivater
DZ2815A1 (fr) Inhibiteurs de protéase.
FI20002262A (fi) Menetelmä proteiinin rakenteen muuttamiseksi
DK1077945T3 (da) Isoquinoliner som urokinaseinhibitorer
EE9900404A (et) Arüülaminotriasolopüridiinide valmistamise meetod
NO994415D0 (no) HIV proteaseinhibitorer
EE04465B1 (et) Vaheühendid HIV-proteaasi inhibiitorite valmistamiseks ja HIV-proteaasi inhibiitorite valmistamismeetodid
TH34294B (th) กระบวนการสำหรับการเตรียมคลอโรเบบโซซาโซล
FI980877A0 (fi) Menetelmä ksyloosin valmistamiseksi

Legal Events

Date Code Title Description
HK1A Erratum in gazette
KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

MM4A Lapsed by not paying the annual fees

Effective date: 20100318